Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis

Endometriosis is a known estrogen-dependent inflammatory disease affecting reproductive-aged women. Common symptoms include pelvic pain, dysmenorrhea, dyspareunia, heavy menstrual bleeding, and infertility. The exact etiology of endometriosis is largely unknown, and, thus, the diagnosis and treatmen...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in Global Women's Health Vol. 3; p. 856316
Main Authors: Chung, Monica S., Han, Sang Jun
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media SA 05.04.2022
Frontiers Media S.A
Subjects:
ISSN:2673-5059, 2673-5059
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endometriosis is a known estrogen-dependent inflammatory disease affecting reproductive-aged women. Common symptoms include pelvic pain, dysmenorrhea, dyspareunia, heavy menstrual bleeding, and infertility. The exact etiology of endometriosis is largely unknown, and, thus, the diagnosis and treatment of endometriosis are challenging. A complex interplay of many molecular mechanisms is thought to aid in the progression of endometriosis, most notably angiogenesis. This mini-review examines our current knowledge of the molecular etiology of endometriosis-associated angiogenesis and discusses anti-angiogenic therapy, in the blockade of endometriosis-associated angiogenesis, as potential non-hormonal therapy for the treatment of endometriosis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
This article was submitted to Quality of Life, a section of the journal Frontiers in Global Women's Health
Reviewed by: Domenico Ribatti, University of Bari Aldo Moro, Italy; Megha Mistry, Norfolk and Norwich University Hospital, United Kingdom
Edited by: Thomas G. Gray, Norfolk and Norwich University Hospital, United Kingdom
ISSN:2673-5059
2673-5059
DOI:10.3389/fgwh.2022.856316